Skip to main content
. 2017 Oct 23;167(3):671–686. doi: 10.1007/s10549-017-4537-5

Fig. 2.

Fig. 2

Best change in target lesions from baseline in 140 evaluable patients with baseline tumor assessment and ≥ 1 post-baseline assessment